Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG

Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry

Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients

Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of the study are followed up at 3-month intervals for 1 year.

Increase Fimasartan if blood pressure is not controlled.

Inclusion Criteria:

• Patients who have been treated or not treated with hypertension from 20 to 80 years of age

• Patients with electrocardiographic left ventricular hypertrophy (In this study, we define left ventricular hypertrophy if one of the following two criteria is met)

  1. RaVL+SV3 > 20mm(M). 16mm(F)
  2. SV1+RV5 or RV6 > 35mm.

• Patients who are taking or expecting Fimasartan

Exclusion Criteria:

• Patients with unstable angina or myocardial infarction within 3 months
• Patients with clinically significant severe valve disease, congenital heart disease, peripheral vascular disease, cerebrovascular disease
• Clinically significant severe congestive heart failure patients
• Patients with renal dialysis
• Clinically significant renal disease patients
• Patients with clinically significant hepatic impairment
• Patients with a history of alcohol or substance abuse
• Patients with hypersensitivity to angiotensin-receptor blocker
• Patients needing angiotensin-receptor blocker drugs other than fimasartan
• For women, pregnancy, Patients who are breastfeeding or planning to become pregnant
• A person who is determined to be inappropriate by the Investigator
• Patients participating in other clinical trials